论文部分内容阅读
目的:探讨艾拉莫德分别联合甲氨蝶呤与双醋瑞因治疗类风湿性关节炎对患者骨代谢的影响差异。方法:收集2012年3月~2015年2月来我院就诊的患者204例,随机分为试验组和对照组,每组102例。试验组给予艾拉莫德联合双醋瑞因治疗,对照组给予艾拉莫德联合甲氨蝾呤治疗,观察两组患者治疗后骨代谢差异。结果:试验组治疗后N-MID、T-P1NP和25(OH)D水平高于对照组,而β-CTX水平及ESR、CRP、压痛关节数和肿胀关节数均低于对照组,分别经t检验比较,差异均具有统计学意义(P<0.05)。结论:艾拉莫德联合双醋瑞因治疗类风湿性关节炎对患者骨代谢的影响较甲氨蝶呤治疗显著。
Objective: To investigate the difference of bone metabolism in patients with rheumatoid arthritis treated with iguratimod respectively with methotrexate and diacerein. Methods: Totally 204 patients who came to our hospital from March 2012 to February 2015 were randomly divided into experimental group and control group, with 102 cases in each group. The experimental group was treated with iguratimod and diacerein, while the control group was treated with iguratimod and methotrexate. The differences in bone metabolism between the two groups after treatment were observed. Results: The levels of N-MID, T-P1NP and 25 (OH) D in the experimental group were significantly higher than those in the control group, while the levels of β-CTX and the numbers of ESR, CRP, tender joint and swollen joint in the experimental group were lower than those in the control group t test, the differences were statistically significant (P <0.05). Conclusion: The effect of iguratimod combined with diacerein on the bone metabolism in patients with rheumatoid arthritis is more significant than that of methotrexate.